Whalesbook
Profit Falls Despite Volume Gains
Nocil's domestic sales volumes grew slightly in Q3 FY26, helped by GST 2.0. However, the company's profits dropped sharply by 28.29% year-over-year to ₹9.25 crore. This shows that rising costs and competition are hurting its earnings, even as revenue stayed flat at ₹315.84 crore. The mix of higher volumes but lower profits highlights the difficulties Nocil faces in turning sales growth into better financial results.
Regulatory Decisions and Export Opportunities
Key regulatory decisions and export market changes are vital for Nocil's future. Investigations into anti-dumping duties for about 40% of Nocil's products are due to finish in 1.5 to 2 months. A positive ruling could boost earnings and ease price pressure from imports, especially from China, South Korea, and Thailand. The new India-EU Free Trade Agreement (FTA) also opens big export chances, offering duty-free access to the EU. Nocil's exports in Q3 FY26 were weak due to seasonal issues and U.S. tariffs, with a U.S. market recovery depending on future tariff changes. Management expects double-digit volume growth in FY27 if these trade and regulatory issues are resolved.
Costs Bite, Margins Shrink, Valuation Debated
Nocil's biggest challenge is unpredictable raw material costs, tied to global oil and natural gas prices. Geopolitical events are pushing up oil costs, increasing expenses for key inputs like benzene and aniline. This has repeatedly squeezed Nocil's profit margins, which have stayed between 7-10% for the last five quarters. The company's returns on capital (ROCE 4.96%) and equity (ROE 3.6%) are low, suggesting it's not generating enough profit from its investments. Fierce competition from cheaper imports, especially from China and Korea, continues to hurt Nocil's pricing power and profits. Although Nocil has a debt-free balance sheet, its sales and profits fell between March 2023 and March 2025. The stock's valuation seems high, trading at a P/E of 37-39x and P/B of 1.3x in early March 2026, especially considering its financial struggles. MarketsMojo rates the stock a 'Strong Sell' due to its valuation and technical outlook.
Capacity Expansion and Future Growth
Nocil is investing ₹250 crore to expand capacity for TDQ antioxidants, which will add 20% to its total capacity. Trial production should start in the first half of this calendar year, with full volumes expected from FY28. The company projects 3-4% volume growth in FY26 and double-digit growth in FY27, banking on better domestic demand and export recovery. Analysts see a potential 40% upside for the stock, targeting ₹189.80 from its current price of ₹135.65. However, this positive outlook must overcome ongoing issues like volatile raw material costs, strong competition, and past profit struggles. Nocil's main task is to use its new capacity and trade deals to manage costs and competition, turning higher volumes into lasting profit growth.